CD83
CD83 is one of a number of genes affected by aberrant somatic hypermutation in B-cell lymphomas, which complicates the interpretation of mutations at this locus.
Mutation tier
| Entity | Tier | Description |
|---|---|---|
| BL | 2-a | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous |
| DLBCL | 1-a | aSHM target and high-confidence DLBCL gene |
| FL | 1-a | aSHM target and high-confidence FL gene |
Mutation incidence
| Entity | source | frequency (%) |
|---|---|---|
| BL | GAMBL genomes+capture | 1.15 |
| BL | Thomas cohort | 1.70 |
| BL | Panea cohort | NA |
| DLBCL | GAMBL genomes | 4.40 |
| DLBCL | Schmitz cohort | 5.74 |
| DLBCL | Reddy cohort | 5.81 |
| DLBCL | Chapuy cohort | 7.26 |
| FL | GAMBL genomes | 1.85 |
Mutation pattern
| Entity | aSHM | Significant selection | dN/dS (missense) | dN/dS (nonsense) |
|---|---|---|---|---|
| BL | Yes | No | 4.396 | 0.000 |
| DLBCL | Yes | No | 4.794 | 14.227 |
| FL | Yes | No | 0.000 | 25.732 |
aSHM regions
| chr_name | hg19_start | hg19_end | region | regulatory_comment |
|---|---|---|---|---|
| chr6 | 14118026 | 14120025 | TSS | active_promoter-strong_enhancer |
[!NOTE] First described in BL in 2019 by Panea RI. First described in DLBCL in 2013 by Morin RD. First described in FL in 2023 by Russler-Germain DA
View coding variants in ProteinPaint hg19 or hg38
View all variants in GenomePaint hg19 or hg38
Citing
If you use the information or data from this site, please cite
Krysta Coyle, Kostiantyn Dreval, Daniel Hodson and Ryan D. Morin. Audit of B-cell cancer genes. Blood Adv (2025) 9 (8): 2019–2031.
Disclaimer
The content in these pages has been populated, in part, by an automated process. Although we have scrutinized every page to ensure accuracy, errors will inevitably exist. If you find an error please report it as an issue and we will address it.
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms.
